Charnwood Molecular worked with a UK Biotech Company, supporting with 4 FTEs, over a 12-month period. Read below to learn more:
- European biotech company (Rare disease target)
- Supported with 2 FTEs for 12 months
- Elaboration of existing hits to elucidate SAR
- Rational design to deliver drug-like compounds
- Compounds screened by client (SPR and cell assays)
- >200 compounds prepared over four series
- Highly potent compounds with good ADME properties, clear SAR and in vivo efficacy
We are flexible in our approach – some clients wish to keep screening in-house, others ask that we manage and drive this process.
Our goal is to provide a tailored service to suit clients’ aspirations and budget, but with a focus on excellence of delivery at all stages.
